Izervay

Drug Overview

Izervay represents a landmark achievement in the Ophthalmology drug category. It is officially classified as a Complement C5 Inhibitor, specifically an RNA aptamer. This medication functions as a high-precision TARGETED THERAPY for the retina, designed to slow the progression of irreversible vision loss in patients with advanced “dry” Age-Related Macular Degeneration (AMD). In the 2026 clinical landscape, it is recognized as a primary defense against the cellular destruction that leads to legal blindness.

• Generic Name: avacincaptad pegol intravitreal solution
• US Brand Name: Izervay
• Route of Administration: Intravitreal Injection (administered directly into the vitreous humor).
• FDA Approval Status: FDA-Approved.
  
  Find out how Izervay, a targeted complement C5 inhibitor, is pioneering the treatment landscape for Geographic Atrophy secondary to AMD.

What Is It and How Does It Work? (Mechanism of Action)

To understand Izervay, one must understand the “overactive” immune response in Geographic Atrophy (GA). GA is characterized by the progressive death of retinal cells. This destruction is driven by the Complement System, a part of the innate immune system that normally clears pathogens but, in AMD, begins to attack the eye’s own healthy retinal pigment epithelium (RPE) cells.

At the molecular level, Izervay acts as a Complement C5 Inhibitor. Once injected, the avacincaptad pegol molecules bind to and inhibit the C5 protein.

By blocking C5, Izervay prevents it from breaking down into smaller components (C5a and C5b) that form the “Membrane Attack Complex.” Without the MAC, the “holes” that are typically punched into retinal cells by the immune system are significantly reduced. This physical stabilization slows the expansion of the “atrophy” (the dead zones in the retina), effectively preserving the remaining healthy vision.

FDA-Approved Clinical Indications

• Primary Indication: Geographic Atrophy (GA) secondary to AMD. It is explicitly indicated for the treatment of GA to slow the rate of retinal lesion expansion.
• Target Population: Patients with advanced dry macular degeneration who have measurable areas of cell loss (atrophy) that threaten the fovea (the center of vision).

Primary Ophthalmology Indications clearly elaborated:

• Stabilizing the Ocular Surface (Retina): By slowing the “march” of cell death, it prevents the atrophy from spreading into the central macula, which is responsible for reading and facial recognition.
• Preserving Visual Acuity: While it cannot “restore” vision already lost to dead cells, it is highly efficacious at maintaining the current field of vision for a longer duration.
• Managing Chronic Disease: It provides a proactive treatment option for a condition that was previously considered untreatable, offering hope to patients with progressive dry AMD.

Dosage and Administration Protocols

Izervay is a long-term therapeutic regimen administered exclusively by a retinal specialist in a sterile clinical environment.

Indication	Standard Dose	Frequency
Geographic Atrophy (GA)	2 mg ( 0.1  mL) per eye	Once monthly (every 28 ± 7 days).

Specific Instructions for Administration: The injection is performed through the pars plana (the “safe zone” of the white of the eye). Prior to injection, the eye is numbed with local anesthesia and cleaned with povidone-iodine to prevent infection. Patients are typically treated for approximately 12 to 24 months, depending on the clinical response and the specialist’s assessment.

Dose Adjustments: No specific adjustments are required for the elderly. Contraindicated in patients with active ocular or periocular infections or severe intraocular inflammation.

Clinical Efficacy and Research Results

Current clinical study data (2020–2026) reinforce that Izervay is highly efficacious in slowing the progression of GA. In pivotal Phase 3 trials (GATHER1 and GATHER2), Izervay demonstrated a 14% to 35% reduction in the rate of GA lesion growth compared to sham (placebo) injections over a 12-month period.

Numerical data indicate that the treatment effect was observed as early as 6 months after starting therapy. Research using Fundus Autofluorescence (FAF) imaging confirms that the “dead zones” in treated eyes grow significantly slower than in untreated eyes. This structural preservation is a critical metric, as every square millimeter of retina saved equates to preserved visual function.

Safety Profile and Side Effects

As an intravitreal injection, Izervay carries risks associated with the procedure and the drug’s effect on retinal signaling. There is currently no Black Box Warning.

Common Side Effects (>10%):

• Conjunctival Hemorrhage: A “broken blood vessel” on the white of the eye (usually harmless).
• Increased Intraocular Pressure (IOP): A temporary pressure spike immediately following the injection.
• Blurred Vision: Temporary “floaters” or blurring from the medication in the vitreous.

Serious Adverse Events:

• Endophthalmitis: A rare but severe internal infection related to the injection.
• Retinal Detachment: A physical tear or separation of the retina.
• Choroidal Neovascularization (CNV): A small percentage of patients (approx. 7%) may develop “wet” AMD while being treated for GA, requiring additional Anti-VEGF injections.

Management Strategies: Clinicians mitigate risks by performing a thorough dilated fundus exam and pressure check after every injection. Patients are instructed to monitor for “wet” AMD symptoms (sudden distortion of lines) throughout treatment.

Research Areas

In the 2026 clinical landscape, research is focused on Combination Therapy and Sustained-Release Systems. Scientists are investigating the use of Izervay alongside Anti-VEGF agents for patients who have “mixed” AMD, as well as the development of port delivery systems that could reduce the frequency of injections.

Generalized research is exploring Genetic Biomarkers to identify which GA patients will respond most robustly to C5 inhibition. In Severe Disease, researchers are evaluating the “Early Intervention” protocol—treating very small lesions before they even threaten the central vision to maximize lifetime visual outcomes.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Visual Acuity (ETDRS) and Tonometry (IOP).
• Ocular Imaging: OCT (Optical Coherence Tomography) and Fundus Autofluorescence (FAF) are mandatory to map the area of atrophy.
• Screening: Rule out active infections or existing “wet” AMD that may require a different primary treatment.

Monitoring and Precautions

• Vigilance: Patients must be monitored for symptoms of infection (pain, light sensitivity) for several days after each injection.
• Lifestyle: Patients should use an Amsler Grid daily at home to check for any sudden changes or wavy lines, which could indicate a transition to “wet” AMD.

Do’s and Don’ts for Ocular Health:

• DO keep your follow-up appointments; the benefit of Izervay is cumulative and requires consistent dosing.
• DO report any “curtain” in your vision or severe redness to your specialist immediately.
• DON’T rub your eye for at least 24 hours after an injection.
• DON’T skip eye exams, even if you don’t feel a “noticeable” improvement—the drug is working to stop vision loss, not restore it.

Legal Disclaimer

This medical information is provided for educational and informational purposes only and does not constitute a doctor-patient relationship or professional medical advice. Izervay is a potent complement inhibitor that must be administered only by a licensed retinal specialist. Always seek the advice of an ophthalmologist regarding the risks and benefits of intravitreal injections for geographic atrophy. Never disregard professional medical advice or delay in seeking it because of something you have read in this guide. Use of Izervay is subject to rigorous patient monitoring and imaging protocols.